



FOR IMMEDIATE RELEASE

October 28, 2004, Lenexa, KS- Dr. Lee Southard, President and Chairman, announced that Dr. Patrick Delafontaine, Chief Division of Cardiology and Director Tulane Cardiovascular Center, Tulane University, and a lead member of the Scientific Advisory Board of VasoGenix Pharmaceuticals, will be presenting a paper on his team's research with Calcitonin Gene Related Peptide at the American Heart Association Annual Meeting in New Orleans November 10th. The title of the paper is **Calcitonin Gene-Related Peptide Prevents Vascular Smooth Muscle Cell Apoptosis via a Novel Mechanism Involving the Insulin-Like Growth Factor 1 Receptor/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway**. The authors are Yangxin Li, Yao-Hua Song, Jessica Mohler, Patrick Delafontaine, Tulane Univ, New Orleans, LA

Dr. Southard said "Preclinical results with CGRP have demonstrated heart damage reductions of 40%. The results of this research help us understand how CGRP works, and substantiates the findings in other scientific literature reports demonstrating the effect of Calcitonin Gene Related Peptide (CGRP) in protecting oxygen deprived cardiac cells. We are encouraged by Dr. Delafontaine's important work because his results add understanding to the mechanism of action of CGRP and its potential as a first line treatment for heart attack. In a heart attack damage to the cardiac cells of the heart is the result of cell death (apoptosis) because of the cells being deprived of oxygen. Minimizing heart muscle damage resulting from heart attack should improve patients' short and long term prognosis and reduce medical care costs associated with the chronic aspects of the disease."

VasoGenix Pharmaceuticals is a biopharmaceutical company developing CGRP as an emergency room treatment for heart attack. Heart attack is America's # 1 killer.